Ademi LLP Launches Investigation Into NextCure Merger Terms

The proposed transaction leaves legacy NextCure investors with a mere 1.21% stake in the combined entity, while Avere Therapeutics stockholders secure 98.79% of the equity. Beyond this valuation gap, the deal includes a contingent value right promising 90% of net proceeds from the monetization of NextCure’s pipeline assets over the next two years.

Ademi LLP is scrutinizing the board’s decision-making process, specifically questioning whether the current deal structure unfairly prioritizes insider change-of-control benefits. The firm is also challenging the merger agreement’s restrictive provisions, which impose significant financial penalties on NextCure should the board attempt to solicit or accept more favorable competing bids. Legal experts are now evaluating whether the directors adequately protected the interests of minority shareholders or if the deal’s constraints effectively stifled a competitive bidding process.